Former CDC Director and Renowned Physician-Scientist Dr. Robert Redfield Joins BPGbio Scientific Advisory Board

Dr. Redfield Joins Scientific Advisory Board as BPGBio Advances its Deep Portfolio of AI-Developed Late-Stage Therapeutics and Diagnostics

BOSTON–(BUSINESS WIRE)–BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced that Dr. Robert Redfield has joined BPGbio’s Scientific Advisory Board. The BPGbio Scientific Advisory Board is composed of the foremost experts spanning various areas of scientific, clinical and biotech specialty as well as patient advocacy, and is vital to advising the company on its scientific, clinical development, and product strategy.

“It truly is an honor and privilege to welcome Dr. Redfield to our Scientific Advisory Board,” said Niven R. Narain, Ph.D., CEO and President of BPGbio. “As arguably one of the top physician-scientists in the world, his career has been dedicated to improving health outcomes across the world. Dr. Redfield’s invaluable lens of experience spans over four decades focused on translating promising research into real-world products. This is perfectly aligned with our corporate mission to usher novel patient-biology based drugs and diagnostics into the market with our Interrogative Biology® platform.”

Robert R. Redfield, MD, is an internist and virologist who rose to become the most senior public health officer in the United States, most recently serving as the 18th Director of the Centers for Disease Control and Prevention (CDC) and Administrator of the Agency for Toxic Substances and Disease Registry. After his time at the CDC, he served as the senior public health advisor to Governor Larry Hogan and the State of Maryland. He has been actively involved in clinical research and the clinical care of chronic human viral infections and infectious diseases, especially HIV, for more than 30 years.

“I am excited to join the Scientific Advisory Board of BPGbio, a company that has demonstrated the potential of harnessing the power of AI to revolutionize the way we prevent, diagnose, and treat diseases, ultimately improving the health and well-being of individuals worldwide,” said Dr. Redfield. “I look forward to working alongside the BPGbio team and other members of the Scientific Advisory Board on this transformative journey.”

Prior to his tenure at the CDC, Dr. Redfield served as the founding Director of the Department of Retroviral Research within the US Military’s HIV Research Program, and retired after 20 years of service in the US Army Medical Corps. He also co-founded the University of Maryland’s Institute of Human Virology with Dr. William Blattner and Dr. Robert C. Gallo and served as the Chief of Infectious Diseases and Vice Chair of Medicine at the University of Maryland School of Medicine, where he and colleagues were able to secure over $500 million in research funding.

Dr. Redfield made several important early contributions to the scientific understanding of HIV, and previously served as a member of the President’s Advisory Council on HIV/AIDS and was appointed as Chair of the International Subcommittee. He is a past member of the Office of AIDS Research Advisory Council at the National Institutes of Health, the Fogarty International Center Advisory Board at the National Institutes of Health, and the Advisory Anti-Infective Agent Committee of the Food and Drug Administration. He earned his M.D. from Georgetown University School of Medicine and B.S. from Georgetown University’s College of Arts.

Dr. Redfield joins an esteemed group of leaders on the BPGbio Scientific Advisory Board, including:

• Chas Bountra, Ph.D., Pro-Vice Chancellor for Innovation and Professor of Translational Medicine and is Director of the Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford.
• Eric Schadt, Ph.D., Dean for Precision Medicine, Professor of Genetics and Genomic Sciences, Mount Sinai Professor of Predictive Health and Computational Biology, and Founder and former CEO of Sema4, a Mount Sinai venture.
• Vikas P. Sukhatme, M.D., Sc.D., Dean of the Emory School of Medicine and Chief Academic Officer of Emory Healthcare.
• Stanley Tucci, Actor, BPGbio’s Senior Advisor of Patient Advocacy and Social Awareness.
• Raymond Pawlicki, former Chief Information Officer (CIO) for Biogen and former CIO for Novartis Pharmaceuticals, AG.
• Linda T. Vahdat, M.D., MBA, Deputy Cancer Center Director, Section Chief of Medical Oncology and Interim Chief of Hematology at Norris Cotton Cancer Center, The Geisel School of Medicine at Dartmouth.
• Eric Nestler, M.D., Ph.D., Nash Family Professor of Neuroscience at the Icahn School of Medicine at Mount Sinai in New York, serving as Dean for Academic Affairs, Chief Scientific Officer, and Director of the Friedman Brain Institute.

About BPGbio, Inc.

Headquartered in the greater Boston, Massachusetts area, BPGbio, Inc., is a leading AI-powered biopharmaceutical company with a human biology focus. BPGbio leverages its Interrogative Biology platform, along with the world’s largest clinically annotated non-governmental biobank, to redefine how patient biology can be modeled using unbiased AI. This approach expedites and safeguards the process of drug discovery across oncology, neurology, and rare diseases. To learn more about BPGbio’s therapeutics and diagnostics pipeline, visit www.bpgbio.com

Contacts

Media Contact
media@bpgbio.com